Var2 Pharmaceuticals Aps

Zymeworks Inc.

Madeleine Dahlback

Mads Daugaard

Ali Salanti

Thor Grundtvig Theander

Morten Nielsen

Thomas Mandel Clausen

John Stephen Babcook

James R Rich

Geoffrey C Winters

Tom Han Hsiao Hsieh

Alexander Laurence Mandel

Bradley John Hedberg

Elyse Marie Josée Bourque

Ali El-Salanti

Tom Han Hsiao Hsie

Alexander L Mandel

The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).

Targeting of chondroitin sulfate glycans

VAR2CSA-drug conjugates having biological activity are disclosed. Methods associated with preparation and use of such conjugates, as well as pharmaceutical compositions comprising such conjugates, are also disclosed.

VAR2CSA-drug conjugates

Growing community of inventors

Swedala, Sweden

Madeleine Dahlback